Nasdaq Biotechnology Index: Holdings, Weighting and Risks
Contents
- Nasdaq Biotechnology Index in 30 seconds
- What is the Nasdaq Biotechnology Index?
- Which stocks are in the Nasdaq Biotech Index?
- How is the NBI calculated and weighted?
- How has the Nasdaq Biotechnology Index performed?
- NBI vs Nasdaq-100
- What moves biotech stocks and the NBI?
- How to invest in the Nasdaq Biotechnology Index
- Strengths and limits of the NBI
- Nasdaq Biotechnology Index: my conclusion
- Frequently asked questions about the Nasdaq Biotechnology Index
- About the author
The well-known iShares biotech ETF IBB stopped tracking the Nasdaq Biotechnology Index in June 2021, yet it is still often named as an NBI fund. That alone shows how easily a biotech index and a fund get mixed up. The NBI itself is a stock index with clear rules: it bundles biotechnology and pharmaceutical companies listed on Nasdaq and behaves quite differently from a single biotech stock.
This guide explains what is inside the NBI, how Nasdaq weights it and which funds really track it. You will see the selection rules, the weighting caps, the largest declines since 2003 and a comparison with the Nasdaq-100, based on the official index history. This article follows our editorial policy and is for education, not investment advice.
Nasdaq Biotechnology Index in 30 seconds
- A sector benchmark. The NBI tracks biotechnology and pharmaceutical companies listed on Nasdaq. Nasdaq has calculated it since 1 November 1993.
- No fixed number of members. Every security that meets the rules is included. On 28 October 2026 there were 245 members; the yearly review is in December.
- Market-cap weighted with caps of 8 and 4 percent. Only the five largest may weigh more than 4 percent. On 30 September 2026, Gilead, Amgen and Vertex led with 8.16, 7.85 and 7.69 percent; the top five made up 33.8 percent.
- Deep, slow declines. Since 2003 the NBI fell more than 25 percent four times; after the 39.4 percent drop from July 2015 to June 2016, a new high came only in May 2020.
- Check the ETF’s index. IBB now tracks an NYSE index; Invesco’s IBBQ and the UCITS ETFs BTEC and SBIO track versions of the NBI.
What is the Nasdaq Biotechnology Index?
The Nasdaq Biotechnology Index is a stock index that tracks the price of biotechnology and pharmaceutical companies listed on Nasdaq. Nasdaq calculates it under the symbol NBI and weights its members by market value with caps.
The NBI is not a security you can buy; it is a yardstick for the sector. To trade it you need a product that tracks it, such as an ETF. According to Nasdaq’s index overview, the index started on 1 November 1993 at 200 points. It closed at 7,256 points on 28 October 2026 and is recalculated once per second on US trading days.
Despite its name, the NBI also holds pharmaceutical companies. Eligible are securities classified under the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceuticals. So the index covers young research firms as well as established drug makers with large sales.
What counts is the listing, not the headquarters. A company’s US listing must be exclusively on Nasdaq, in the Global Select Market or the Global Market. That is why foreign companies such as BioNTech from Mainz, argenx or Sanofi are included through their US depositary receipts. Large drug makers listed on the New York Stock Exchange, such as Eli Lilly or Pfizer, are not.
Which stocks are in the Nasdaq Biotech Index?
The NBI includes every security that meets the rules; there is no maximum number. Nasdaq’s index methodology sets the eligibility rules. Once a year Nasdaq checks all candidates, and those that pass are included.
- Industry: ICB biotechnology or pharmaceuticals subsector.
- Listing: US listing only on Nasdaq Global Select Market or Global Market. Common stocks, ADRs and some other share types are eligible; if an issuer has several share classes, all of them.
- Size: at least $200 million market value.
- Trading: an average of at least 100,000 shares a day, measured from the start of the year to the reference date.
- Trading history: at least three full calendar months, not counting the month of listing.
An ADR (American depositary receipt) is a certificate traded on a US exchange that represents shares of a foreign company. For ADRs, Nasdaq counts only the depositary shares actually issued, not all shares of the group. A large foreign company can therefore weigh much less in the NBI than its total market value suggests.
The number of members changes from year to year. On 28 October 2026 Nasdaq’s member list showed 245 securities. The annual reconstitution is announced in early December and takes effect after the close on the third Friday of December. If a company is taken over during the year, Nasdaq removes it as soon as the deal is considered highly probable, and it is replaced only at the next reconstitution.
| Company | Symbol | Weight |
|---|---|---|
| Gilead Sciences | GILD | 8.16% |
| Amgen | AMGN | 7.85% |
| Vertex Pharmaceuticals | VRTX | 7.69% |
| Moderna | MRNA | 5.04% |
| Regeneron Pharmaceuticals | REGN | 5.03% |
| Revolution Medicines | RVMD | 2.88% |
| Illumina | ILMN | 2.71% |
| Biogen | BIIB | 2.19% |
| Alnylam Pharmaceuticals | ALNY | 2.16% |
| Roivant Sciences | ROIV | 1.73% |
The ten largest NBI members according to Nasdaq’s factsheet as of 30 September 2026, together 45.44 percent of the index. Weights change with every price; Nasdaq publishes the current member list.
The top five make up almost 34 percent, the top ten just over 45 percent. The other 235 or so members share the rest. Reading the NBI therefore means reading mostly Gilead, Amgen and Vertex, plus a long tail of smaller biotech firms, many of which have no drug on the market yet. Older factsheets with other leaders describe a past state and are not today’s list.
How is the NBI calculated and weighted?
A modified market-cap weighted index first weights each stock by its market value and then caps single weights at fixed limits, so size still matters but no single member dominates.
The NBI applies its caps in two stages. First, each member gets the weight that matches its market value relative to all members. In the first stage, any weight above 8 percent is capped. In the second stage, the five largest keep their weight and all others are limited to 4 percent.
| Rule | Value |
|---|---|
| Maximum weight per member | 8% |
| Members above 4% | at most the five largest |
| All others | at most 4% |
| Rebalancing | quarterly, effective after the third Friday of March, June, September and December |
| Reconstitution | once a year, effective after the third Friday of December, market data as of end of October |
Weighting and review rules according to Nasdaq’s index methodology, read on 29 October 2026; the latest change entry shown in the document is dated 19 March 2024.
Between reviews, weights can drift above their caps. Nasdaq calculates each rebalancing with shares and prices from the prior month end, so end of February, May, August and November. After that, weights move with prices. That is why Gilead stood at 8.16 percent on 30 September, slightly above the 8 percent cap; the next rebalancing in December spreads the excess again.
A price index tracks only price changes, while a total return index also reinvests dividends. The familiar NBI level is a price index. According to Nasdaq’s index versions, there is also the total return index XNBI, which reinvests dividends on the ex-date, and a net version, XNBINNR, which reinvests 70 percent of dividends after an assumed 30 percent tax. Many biotech firms pay no dividend, so the versions are not far apart, but when you compare returns you should know which one you are looking at.
How has the Nasdaq Biotechnology Index performed?
Over the long run the NBI has risen strongly, but with long dry spells. Nasdaq’s freely available daily series starts on 21 January 2003 at 515 points. The record close came on 19 August 2026 at 7,405 points; on 28 October the index was about 2 percent below it. The chart uses a log scale, on which equal percentage moves look equally large, and marks the four largest declines in orange.
Click to enlargeThe series shows four declines of more than 25 percent since 2003. Each is measured from the highest close up to then to the lowest close before the next high. What stands out is less the depth than the duration: after the July 2015 high it took almost five years to reach a new record, after the August 2021 high just over four years.
| High to low | Decline | New high |
|---|---|---|
| 07/2015 to 06/2016 | −39.4% | 05/2020 |
| 08/2021 to 06/2022 | −38.5% | 11/2025 |
| 08/2008 to 03/2009 | −34.7% | 03/2010 |
| 04/2004 to 08/2004 | −26.9% | 02/2006 |
The four NBI declines of more than 25 percent since 21 January 2003 (high and low: 20 Jul 2015 and 27 Jun 2016, 9 Aug 2021 and 13 Jun 2022, 14 Aug 2008 and 9 Mar 2009, 27 Apr 2004 and 9 Aug 2004), daily closes from Nasdaq’s index history, price index in US dollars. New high: first close above the old record. Own calculation as of 28 October 2026.
| Year | NBI | Nasdaq-100 |
|---|---|---|
| 2008 | −12.6% | −41.6% |
| 2013 | +66.0% | +36.9% |
| 2016 | −21.3% | +7.3% |
| 2022 | −10.1% | −32.4% |
| 2023 | +4.6% | +55.1% |
| 2025 | +33.4% | +21.0% |
| 2026 to 28 Oct | +27.7% | +18.7% |
Calendar-year change, close to close, total return indices XNBI and XNDX with dividends reinvested, in US dollars. Calculated from Nasdaq’s daily series as of 28 October 2026; own calculation.
As a whole, the NBI swings less wildly than its reputation suggests. Nasdaq’s factsheet gives an annualized volatility of 23.37 percent for the ten years to September 2026 and an average return of 9.64 percent a year, both for the total return index XNBI. By our calculation, volatility from 25 September 2003 to 28 October 2026 was 23.7 percent for the NBI and 21.9 percent for the Nasdaq-100 (standard deviation of daily log returns, annualized, both as total return indices). These figures describe the past, not the future; with drawdowns this long, your position size matters.
The calm of the index does not apply to its single stocks. A small biotech firm with one drug candidate can lose a large part of its value in a day after a failed clinical trial. In the NBI such a member barely registers, because it weighs only a fraction of a percent. The event risk of the single stock does not disappear in the index; it is diluted.
NBI vs Nasdaq-100
The Nasdaq-100 holds some biotech stocks, but technology dominates it; the NBI is pure biotech and pharma. Setting both indices to the same start value shows when biotech led or lagged the wider market. The chart compares both as total return indices with dividends, both starting at 100 on 25 September 2003.
Click to enlargeSince September 2003 the NBI grew 10.8-fold and the Nasdaq-100 27.4-fold. Biotech led during parts of the period around 2015; after that, the technology market pulled far away. Since the end of 2015 the NBI gained 120 percent and the Nasdaq-100 just over 600 percent. The NBI did better in ten of the 23 years from 2004 to 2026, counting 2026 only to 28 October.
In return, the NBI fell less in the big crises. In 2008 it lost 12.6 percent while the Nasdaq-100 lost 41.6 percent; in 2022 it was 10.1 against 32.4 percent. The largest decline of the total return index since 2003 was 39.2 percent, against 53.4 percent for the Nasdaq-100. Medicines are needed in a recession too, which supports the large pharma names. That is no guarantee for the next crisis. Our sector rotation guide checks how the whole health care sector did in three US recessions.
Divide the NBI by the Nasdaq-100 and you get biotech’s relative strength. The line shows whether the biotech and pharma stocks in the NBI are doing better or worse than the Nasdaq-100, as explained in our guide to relative strength. It does not measure money flowing in or out, and it is not an early warning: it shows which group is doing better now, not when a trend ends.
A different biotech index can paint a very different picture. The S&P Biotechnology Select Industry Index, which the XBI ETF tracks, holds only biotech without pharma and weights its members roughly equally. There, a small research firm counts almost as much as a large company; in the NBI the heavyweights dominate. Neither is the better index; they measure different things. Our Nasdaq-100 forecast covers the tech index itself.
What moves biotech stocks and the NBI?
Biotech prices depend on events that no chart predicts. Five forces shape the sector. They show up first in trial data, regulatory decisions and quarterly results, and only then in the price.
- Clinical trials: a drug candidate goes through several test phases in humans. Good or bad data move small members with few projects most.
- Approval: in the US, the FDA reviews the data and decides on approval. The date is often known, the outcome is not.
- Patents: when protection for a best-selling drug ends, cheaper copies can follow. This hits mainly the large members with high index weights.
- Financing: many small firms are not yet profitable and need fresh capital. Whether they get it, and at what price, also depends on the mood in capital markets.
- Takeovers: large companies buy research firms to fill their pipelines. For the target that often means a price jump, for the index a departure.
Takeovers change the NBI directly. According to the methodology, Nasdaq removes a company as soon as a takeover is considered highly probable, for example after regulatory approval. A replacement comes only at the next reconstitution in December, so the number of members can shrink during the year.
Key dates are the earnings of the heavyweights and the review dates. Because Gilead, Amgen, Vertex, Moderna and Regeneron make up about a third of the index, their quarterly reports move the whole NBI. So do the rebalancings in March, June, September and December, when index funds adjust their holdings.
How to invest in the Nasdaq Biotechnology Index
You cannot buy the NBI directly, only products that track it. Many biotech ETFs have similar names and still follow different indices. The list shows which index the best-known funds track according to their providers, read on 29 October 2026.
- iShares IBB (US): NYSE Biotechnology Index, not the NBI.
- SPDR XBI (US): S&P Biotechnology Select Industry Index, not the NBI.
- Invesco IBBQ (US): Nasdaq Biotechnology Index, so it tracks the NBI.
- iShares BTEC (UCITS, Europe): net version of the Nasdaq Biotechnology Index.
- Invesco SBIO (UCITS, Europe): Nasdaq Biotechnology total return index.
Index according to each provider’s product page or factsheet and Nasdaq’s product list, read on 29 October 2026. ISINs of the UCITS ETFs: iShares Nasdaq US Biotechnology UCITS ETF IE00BYXG2H39, Invesco Nasdaq Biotech UCITS ETF IE00BQ70R696.
The best-known biotech fund no longer tracks the NBI. According to the iShares product page, the iShares Biotechnology ETF with the symbol IBB has tracked the NYSE Biotechnology Index since 21 June 2021; before that, its benchmark was the NBI. An NYSE article describes how the switch reshaped the biotech index landscape. Nasdaq’s product list no longer shows IBB as an NBI fund, but it does list the Invesco Nasdaq Biotechnology ETF, IBBQ.
Outside the US, access depends on local rules. In the European Union, retail brokers generally cannot offer a fund to retail investors without the key information document that the PRIIPs regulation requires, and US-domiciled ETFs usually do not provide one. Unlike for the SOX, two European UCITS ETFs track the NBI. Whether your broker offers them is best checked with the ISIN.
The two UCITS ETFs track different versions of the NBI. According to its factsheet, the iShares Nasdaq US Biotechnology UCITS ETF buys the stocks itself and measures itself against the net version of the index. The Invesco Nasdaq Biotech UCITS ETF tracks the total return index XNBI synthetically, through swaps with banks. The index itself is in US dollars, so investors in other currencies also take on currency risk.
When you choose a fund, check its index in the factsheet, not just its name. A fund on a roughly equal-weighted biotech index behaves differently from one on the NBI with its heavyweights. Check the costs and the replication method in the provider’s documents. Our SOX index guide explains the same trap for semiconductor ETFs, and our guide to the Dow transport index shows it for transport ETFs.
Strengths and limits of the NBI
The NBI is a good benchmark for biotech on Nasdaq, but not a picture of the whole healthcare sector. It bundles about 245 biotech and pharma stocks in one number, its rules are public with clear caps and fixed review dates, and it dilutes the trial and approval risk of single firms. Compared with the Nasdaq-100, it shows whether biotech leads or lags.
Its limits are just as clear. It includes only Nasdaq-listed stocks, so large drug makers on the NYSE are missing. The top five make up about a third, while the many small firms weigh little. After its large declines since 2003, it took up to five years to reach a new high, and a comparison with other indices describes the past, not a reliable signal for tomorrow.
Nasdaq Biotechnology Index: my conclusion
The NBI is the sector gauge for biotech and pharma on Nasdaq. It includes every security that meets its rules, weights them by market value with caps of 8 and 4 percent, and is shaped strongly by a few heavyweights such as Gilead, Amgen and Vertex.
As a whole it is calmer than its single stocks, but not without risk. Since 2003 it fell more than 25 percent four times, and twice the recovery took more than four years. When you invest, the index is in the small print: the well-known IBB no longer follows the NBI, so check the factsheet, the return version and whether the product is available to you.
Frequently asked questions about the Nasdaq Biotechnology Index
What does the Nasdaq Biotechnology Index measure?
It tracks the price of biotechnology and pharmaceutical companies listed on Nasdaq. The NBI is a stock index that Nasdaq has calculated since 1 November 1993. It weights its members by market value with caps.
How many stocks are in the NBI?
There is no fixed number. The NBI includes every security that meets its rules; on 28 October 2026 there were 245 members. Nasdaq reselects them once a year in December, and companies that are taken over leave earlier.
Which are the largest stocks in the Nasdaq Biotech Index?
The three largest were Gilead, Amgen and Vertex. On 30 September 2026, Gilead Sciences weighed 8.16 percent, Amgen 7.85 and Vertex 7.69 percent, followed by Moderna and Regeneron. Nasdaq publishes the current list.
Does the iShares IBB ETF track the Nasdaq Biotechnology Index?
IBB no longer tracks the NBI. According to iShares, IBB has tracked the NYSE Biotechnology Index since 21 June 2021; before that it tracked the NBI. A US ETF that tracks the NBI is Invesco’s IBBQ.
Is the NBI the same as XBI?
XBI is an ETF tracking a different biotech index. It follows the S&P Biotechnology Select Industry Index, which holds only biotech without pharma and weights its members roughly equally. In the NBI, the large members dominate.
Is the NBI more volatile than the Nasdaq-100?
As a whole, only slightly. From 25 September 2003 to 28 October 2026, the annualized volatility of the total return index was 23.7 percent for the NBI and 21.9 percent for the Nasdaq-100, by our calculation, and the NBI’s largest decline was smaller. Single biotech stocks are a different matter: their event risk around trial data and approvals is far higher.
This English edition is based on our German edition on kagels-trading.de and has been adapted for international readers.
More Markets and Brokers guides
- Open your first account
What Is a Brokerage Account? A US Beginner's Guide
How to open and fund a US brokerage account, cash vs margin, what it costs and what SIPC and FDIC really cover.
- Know what trading really costs
Trading Costs: Every Fee You Pay and How to Cut It
Spread, commissions, SEC and FINRA fees, market data, margin interest and tax, with yearly totals for three trading styles.
- Choose a broker
Interactive Brokers Review 2026: Fees and Platforms
Fees, platforms, investor protection and real futures commissions from a client since 1996.
- Choose an options broker
tastytrade Review 2026: Options Fees, Margin and Safety
tastytrade from an options trader's own account and its October 2026 fee schedule: fees, the 6.75% margin rate, safety and FINRA fines.
- Check an offshore broker
PU Prime Review 2026: FCA Warning, Licences and Costs
Which PU Prime company you contract with, what the FCA warning means, and what 1:1000 leverage and the deposit bonus do to your account.
- Check an EU CFD broker
Tradeview Review 2026: Tradeview Europe, MFSA and Costs
What the Malta licence of Tradeview Europe covers, how it differs from the Cayman company, and what the three MetaTrader 5 accounts cost.
- Check ZuluTrade
ZuluTrade Review 2026: Costs, Regulation and US Status
Who runs the copy trading platform, what it costs through your broker, why the US was missing from its sign-up form and what the CFTC fined its US company for.
- Check CopyX
CopyX Review 2026: Is TAG Markets Copy Trading Legit?
Who runs the TAG Markets copy trading platform, which regulators warn about it, why US residents are excluded and how fast the 12x Amplify account eats your deposit.
- Choose a US forex broker
OANDA Review 2026: Fees, TradingView and US Rules
OANDA from its own pages and NFA records: spreads and fees, TradingView and the demo, FIFO and three penalties.
- Check a commission-free app broker
Webull Review 2026: Fees, Margin Rates and Safety
Webull from its own fee schedule and FINRA records: what is free, margin rates and Premium, overnight trading, crypto and three fines.
- Understand your price
Market Makers: Who Sets Your Price and How They Profit
How market makers earn on the spread, who sets prices at German trading venues and what the EU ban on payment for order flow changed.
- Size up a bull market
Bull Market: How Long It Lasts and How to Spot the End
When a rise becomes a bull market, how long the 27 completed S&P 500 bull markets since 1928 lasted and gained, and where the current one stands.
- Read bond market stress
MOVE Index: The VIX of the Bond Market, Explained
What the MOVE index measures, which readings signal stress, how it differs from the VIX and where its limits are.
- Read stock market fear
VIX Index: What the Fear Gauge Measures and Normal Levels
What the VIX measures, which levels have been normal since 1990, how closely it tracks the S&P 500 and how VIX futures, options and ETPs work.
- Read the risk mood
Risk-On vs Risk-Off: Meaning, Assets and Indicators
What risk-on and risk-off mean, which assets rise and fall in each mode, five market shocks since 2008 and the VIX, DXY and AUD/JPY signals.
- Read market sentiment
Fear and Greed Index: How It Works, Tested Since 2021
How CNN builds its Fear and Greed Index from seven measures, what the zones mean and how the S&P 500 moved after readings below 20.
- Size up a bear market
Bear Market: How Long It Lasts and How to Spot One
When a decline becomes a bear market, how long the 27 S&P 500 bear markets since 1928 lasted, how long the recovery took and why Bitcoin had three since 2025.
- Trade an index CFD
Index CFDs at Interactive Brokers: Symbols, Costs and Trading
All 13 IBKR index CFDs, margin, stop and close-out worked through for IBDE40, financing, UK hours and the TradingView limit.
- Size an index future
Micro Futures: MES vs MNQ, Tick Values and Risk
MES and MNQ tick values, a worked sizing example from the stop with costs and slippage, and why margin is not your risk.
- Choose between futures and CFDs
Futures vs CFDs: Regulation, Order Execution and Costs
Who your counterparty is, EU, UK and US rules, how stops are triggered on CME and at CFD providers, and booked costs in a DAX example.
- Understand the IBKR Exposure Fee
IBKR Exposure Fee: What It Is and How to Reduce It
Why Interactive Brokers charges a daily fee on high-risk accounts, why weekends count, where to find it and how to reduce it, with a real 1.12 euro notice.
- Read the futures curve
Contango vs Backwardation: Futures Curves Explained
What contango and backwardation mean, what rolling does to a position in each case, and real gold, oil and gas curves from 28 October 2026.
- Understand the spot market
Spot Market Explained: Definition and Settlement Times
What a spot market is, why two days is a minimum and not a limit, and when stocks settle at T+1 in the US, EU, UK and Switzerland.
- Choose a silver future
Silver Futures: SI vs Micro Silver vs 100-oz SIC
SI, Micro Silver and the 100-ounce SIC compared by tick value, risk per contract, margin and December 2026 deadlines.
- Read the chip sector
SOX Index: Holdings, Weighting and How to Use It
What the SOX holds, how Nasdaq caps the weights, its largest declines since 2004 against the Nasdaq-100 and which ETFs really track it.
- Read the transport sector
Dow Jones Transportation Average: Stocks and Dow Theory
The 20 stocks in the Dow transport index, why the share price sets their weight, declines since 1992 and what Dow Theory can and cannot tell you.
- Read the French market
CAC 40 Index Explained: All 40 Stocks, Weights and Trading Hours
All 40 CAC 40 stocks, how Euronext caps the weights at 15 percent, trading hours in Eastern Time and how it differs from the DAX.
- Research stocks
InvestingPro Review: Screener, ProPicks AI and WarrenAI
What the InvestingPro screener, ProPicks AI and WarrenAI do, what Pro and Pro+ cost and who needs which plan.
- Judge a stock-picking newsletter
Motley Fool Stock Advisor Review: Cost and Track Record
What Motley Fool Stock Advisor costs after the first year, how the advertised return is calculated, refund and renewal terms, and who it suits.
- Use the free news portal
Investing.com Review: Free Tools, Data and Limitations
What the free Investing.com portal does well, where the quote prices come from and when InvestingPro is worth paying for.
- Use Forex Factory
Forex Factory: Calendar, Forums and Tools Explained
How to read and set up the Forex Factory calendar, and what its forums, trades feed, news, broker guide and Trade Explorer offer.
- Find real AI revenue
AI Stocks 2026: How Listed Companies Earn From AI
Which listed companies earn from AI in cloud, software, infrastructure and chips, disclosed AI revenue against hope, plus AI ETFs and risks.
- Compare AI data center suppliers
AI Infrastructure Stocks: 10 Data Center Suppliers Compared
Ten suppliers for power, cooling, servers and optics compared on free cash flow, customer concentration and next dates, with filters and a two-stock comparison.
- Follow an IPO
Anthropic Stock: IPO Date, Valuation and How to Invest
Where the Anthropic IPO stands, how the valuation compares with revenue and how to get exposure before and after the listing.
- Invest in OpenAI before the IPO
OpenAI Stock: Can You Buy It, and Who Owns OpenAI?
Why there is no OpenAI stock yet, who owns OpenAI, where the IPO stands and how much OpenAI you get through Microsoft or SoftBank.
- Understand a stock split
Stock Splits Explained: Forward and Reverse Splits
What forward and reverse splits change and what they do not, the dates that matter, what happens to options and the $1 listing rule.
- Analyze a company
Fundamental Analysis: 12 Ratios, a Worked Example, 5 Steps
Twelve ratios with formulas and rules of thumb, worked through Microsoft's 2026 annual report, a five-step process and the fundamentals of forex, commodities and crypto.
- Value a stock
Value Investing: Intrinsic Value, Margin of Safety, Traps
Intrinsic value against price, a worked DCF with a sensitivity table, Coca-Cola as a real example, the value premium since 1926 and value traps.
- Value a new listing
SpaceX Stock (SPCX): Valuation, Risks and How to Buy
How to buy SpaceX stock, what the company is worth after the IPO and which risks the lock-up calendar brings.